Stock Financial Ratios, Dividends, Split History

LILA / Liberty Global plc LiLAC Class A financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price19.50
Volume137,500.00
Market Cap ($M)1,011.05
Enterprise Value ($M)44,800.17
Book Value ($M)10,652.40
Book Value / Share20,351.42
Price / Book0.08
NCAV ($M)-54,335.50
NCAV / Share-103,808.01
Price / NCAV-0.02
Income Statement (mra) ($M)
Revenue18,280.00
EBITDA2,349.20
Net Income-1,049.50
Balance Sheet (mrq) ($M)
Cash & Equivalents977.10
Cash / Share1,866.75
Assets80,973.50
Liabilities68,008.20
Quick Ratio0.37
Current Ratio0.37
Share Statistics
Common Shares Outstanding230,773,233
Common Shares Outstanding410,472,517
Common Shares Outstanding6252,805,601
Common Shares Outstanding523,423
Common Shares Outstanding5581,034,556
Common Shares Outstanding312,630,744
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.02
Return on Assets (ROA)-0.01
Return on Equity (ROE)-0.07
Identifiers and Descriptors
CUSIPG5480U138
Central Index Key (CIK)1570585
Industry Groups
SIC 4841 - Cable and Other Pay Television Services

Split History

Stock splits are used by Liberty Global plc LiLAC Class A to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Peers - Cable and Other Pay Television Services (4841)

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

11h - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

11h - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

Related News Stories

EU mergers and takeovers (April 24)

2018-04-24 reuters
BRUSSELS, April 24 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process: (88-0)

UPDATE 1-UK Stocks-Factors to watch on April 24

2018-04-24 reuters
April 24 (Reuters) - Britain’s FTSE 100 index is seen opening 10 points higher at 7,409 on Tuesday, according to financial bookmakers,with futures up 0.10 percent ahead of the cash market open. (18-0)

EU mergers and takeovers (April 23)

2018-04-23 reuters
BRUSSELS, April 23 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process: (74-0)

EU mergers and takeovers (April 17)

2018-04-17 reuters
BRUSSELS, April 17 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process: (78-0)

SeaChange International's (SEAC) CEO Ed Terino on Q4 2018 Results - Earnings Call Transcript

2018-04-16 seekingalpha
Greetings, and welcome to the SeaChange International’s Fourth Quarter 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation [Operator Instructions]. As a reminder, this conference is being recorded. (12-0)

CUSIP: G5480U138